May & Baker Nigeria is one of the oldest names in Nigerian pharmaceuticals, and its latest results show a company that has suddenly found much firmer footing. Full nameMay & Baker Nigeria Plc Tickers / exchangeMAYBAKER on the Nigerian Exchange (XNSA) HeadquartersLagos, Nigeria SectorPharmaceuticals and healthcare EmployeesNot published in available sources Market valueNot published in available sources Yearly sales (revenue)₦38.26 billion (US$28.8 million), year ended 31 Dec 2025 Net profit₦4.44 billion (US$3.3 million), year ended 31 Dec 2025 Net margin11.6% (our calculation) Return on equity32.5% (our calculation) Price-to-earningsNot published in …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times